title: Factors influencing anti-asthmatic generic drug consumption in Morocco: 1999-2010.
abstract: BACKGROUND
  The increasing availability of generic drugs (GD) resulted in a remarkable reduction in treatment costs that allowed a better access to health care.The aim of this study is to evaluate the share of anti-asthmatic generic drugs during the period 1999-2010 in Morocco and to look at the factors influencing generic development.
  
  
  METHODS
  In this study, we used Moroccan sales data from IMS Health (Intercontinental Marketing Services). The consumption of the drugs was expressed in DDD/1000 inhabitants/day according to the WHO ATC/DDD methodology.
  
  
  RESULTS
  Between 1999 and 2010, anti-asthmatic consumption increased from 3.91 to 14.43 DDD/1000 inhabitants/day. The market of anti-asthmatic generic drugs progressed from 1.83 (47%) to 2.18 (23%) DDD/1000 inhabitants/day from 1999 to 2010. In 2010, inhaled glucocorticosteroids ranked first (0.83 DDD/1000 inhabitants/day), followed by inhaled short acting beta agonists (0.73 DDD/1000 inhabitants/day). The number of brands went from 27 in 1999 to 34 in 2010, with a generic share increasing from 55.55% to 70.59%. The number of anti-asthmatic pharmaceutical preparations increased from 57 to 64 during the same period, of which 31 and 42 were generic preparations. In 2010, the total cost of anti-asthmatic dugs was about 22 million euro, the generics representing 14 million euro.
  
  
  CONCLUSIONS
  Despite the introduction of a compulsory insurance scheme called "AMO", that allows a refund for 69.5% of anti-asthmatic specialties marketed in Morocco, anti-asthmatic generic drug consumption remains limited. The Moroccan market is still largely dominated by the originator drugs with still valid patents.
authors.affiliation: Research team of Pharmacoepidemiology & Pharmacoeconomics, Faculty of Medicine and Pharmacy of Rabat. Morocco, University Mohammed V -Souissi, Rabat, Morocco.
authors.forename: Imane
authors.initials: I
authors.lastname: Ghanname
authors.affiliation: Research team of Pharmacoepidemiology & Pharmacoeconomics, Faculty of Medicine and Pharmacy of Rabat. Morocco, University Mohammed V -Souissi, Rabat, Morocco.
authors.forename: Samir
authors.initials: S
authors.lastname: Ahid
authors.affiliation: Research team of Pharmacoepidemiology & Pharmacoeconomics, Faculty of Medicine and Pharmacy of Rabat. Morocco, University Mohammed V -Souissi, Rabat, Morocco.
authors.forename: Ghizlane
authors.initials: G
authors.lastname: Berrada
authors.affiliation: Department of marketing, Pharmed, Casablanca, 20 380 Morocco.
authors.forename: Abdelmjid
authors.initials: A
authors.lastname: Belaiche
authors.affiliation: Research team of Pharmacoepidemiology & Pharmacoeconomics, Faculty of Medicine and Pharmacy of Rabat. Morocco, University Mohammed V -Souissi, Rabat, Morocco.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Hassar
authors.affiliation: Research team of Pharmacoepidemiology & Pharmacoeconomics, Faculty of Medicine and Pharmacy of Rabat. Morocco, University Mohammed V -Souissi, Rabat, Morocco.
authors.forename: Yahia
authors.initials: Y
authors.lastname: Cherrah
keywords: Antiasthmatics; Compulsory health insurance; Drug consumption; Generic drugs; Morocco; Originator drugs; Pricing